Your browser is no longer supported. Please, upgrade your browser.
Settings
NBIX Neurocrine Biosciences, Inc. daily Stock Chart
NBIX [NASD]
Neurocrine Biosciences, Inc.
Index- P/E- EPS (ttm)-1.63 Insider Own1.20% Shs Outstand89.94M Perf Week5.40%
Market Cap7.14B Forward P/E44.73 EPS next Y1.78 Insider Trans-32.06% Shs Float88.19M Perf Month-6.40%
Income-142.50M PEG- EPS next Q-0.31 Inst Own- Short Float6.98% Perf Quarter-1.59%
Sales161.60M P/S44.19 EPS this Y0.50% Inst Trans-0.01% Short Ratio7.26 Perf Half Y33.63%
Book/sh4.20 P/B18.90 EPS next Y947.60% ROA-21.70% Target Price105.36 Perf Year54.14%
Cash/sh5.74 P/C13.84 EPS next 5Y- ROE-43.50% 52W Range41.76 - 92.98 Perf YTD2.33%
Dividend- P/FCF- EPS past 5Y- ROI-17.70% 52W High-14.61% Beta0.32
Dividend %- Quick Ratio- Sales past 5Y24.90% Gross Margin99.20% 52W Low90.13% ATR3.03
Employees400 Current Ratio10.20 Sales Q/Q- Oper. Margin-81.30% RSI (14)48.31 Volatility3.43% 3.98%
OptionableYes Debt/Eq0.99 EPS Q/Q115.10% Profit Margin-88.20% Rel Volume0.71 Prev Close78.18
ShortableYes LT Debt/Eq0.99 EarningsMay 15 AMC Payout- Avg Volume847.31K Price79.40
Recom1.60 SMA200.36% SMA50-4.82% SMA20014.97% Volume600,025 Change1.56%
Feb-22-18Reiterated Needham Buy $95 → $110
Nov-02-17Reiterated H.C. Wainwright Buy $130 → $139
May-10-17Reiterated H.C. Wainwright Buy $100 → $130
May-05-17Initiated BofA/Merrill Buy $70
Jan-27-17Upgrade Oppenheimer Perform → Outperform
Nov-22-16Initiated Oppenheimer Perform
Nov-03-16Initiated Deutsche Bank Buy $65
Oct-18-16Initiated Needham Buy $62
Oct-04-16Resumed Leerink Partners Outperform $70
Jun-29-16Initiated H.C. Wainwright Buy $80
Oct-12-15Reiterated Leerink Partners Outperform $67 → $71
Oct-08-15Reiterated Piper Jaffray Overweight $86 → $96
Sep-16-15Reiterated Piper Jaffray Overweight $82 → $86
Aug-18-15Resumed Jefferies Buy
May-22-15Reiterated Piper Jaffray Overweight $56 → $64
May-22-15Reiterated Nomura Buy $61 → $69
Mar-04-15Initiated Barclays Overweight $60
Feb-10-15Reiterated Deutsche Bank Buy $35 → $45
Feb-05-15Initiated Robert W. Baird Outperform $40
Jan-09-15Reiterated Deutsche Bank Buy $25 → $35
Apr-19-18 07:52AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Apr-18-18 04:01PM  Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting PR Newswire
Apr-10-18 10:16AM  FDA needs more time to review AbbVie, Neurocrine's uterine pain drug Reuters
09:05AM  UPDATE 1-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug Reuters
09:05AM  FDA extends review for AbbVie, Neurocrine's uterine pain drug Reuters
08:15AM  AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain PR Newswire
08:07AM  A Sixth Sense For Biotech Has Made Joe Edelman A Hedge Fund Star Forbes
Mar-28-18 06:04AM  3 Biotechs That Could Get Big Boosts in April Motley Fool
Mar-20-18 07:26AM  Loss-Making Neurocrine Biosciences Inc (NASDAQ:NBIX) Expected To Breakeven Simply Wall St.
Mar-13-18 03:00PM  Is This AbbVie's Next Blockbuster Drug? Motley Fool
Mar-07-18 01:15PM  Neurocrine Biosciences to Present at Upcoming Healthcare Conferences PR Newswire
Feb-21-18 08:34AM  AbbVie, Neurocrine shares rise after positive results for uterine fibroids drug MarketWatch
08:00AM  AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids PR Newswire
Feb-20-18 02:04PM  5 Stocks to Outperform in 2018s Volatile Market Investopedia
Feb-16-18 03:00PM  NBIX: Will File an NDA for Opicapone in 1H19 Zacks Small Cap Research
Feb-14-18 04:01PM  Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson's Disease Based on Existing Pivotal Clinical Trial Data PR Newswire
10:11AM  Edited Transcript of NBIX earnings conference call or presentation 13-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
Feb-13-18 04:17PM  Neurocrine misses 4Q profit forecasts Associated Press
04:01PM  Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018 PR Newswire
12:30PM  Neurocrine Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Feb-08-18 01:15PM  Neurocrine Biosciences to Present at the Leerink Partners 7th Annual Global Healthcare Conference PR Newswire -5.05%
Feb-07-18 07:15PM  Neurocrine Biosciences Inc (NBIX) CEO Kevin Charles Gorman Sold $8.5 million of Shares GuruFocus.com
Feb-06-18 01:15PM  Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2017 Financial Results PR Newswire
Jan-23-18 08:10AM  New Research Coverage Highlights Leidos, Neurocrine Biosciences, M&T Bank, PennyMac Financial Services, CTS, and S&T Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jan-11-18 10:17AM  Elagolix May Advance the Treatment Paradigm in Womens Health Market Realist
Jan-10-18 05:20PM  How Did Bioverativ Perform in 3Q17? Market Realist
03:49PM  Analysts Recommendations for Bioverativ in January 2018 Market Realist
Jan-09-18 08:02AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Jan-08-18 05:52AM  Should You Be Concerned About Neurocrine Biosciences Incs (NASDAQ:NBIX) -54.35% Earnings Decline? Simply Wall St.
Jan-07-18 01:01PM  Neurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer PR Newswire
01:00PM  Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones PR Newswire
Jan-02-18 04:01PM  Neurocrine Biosciences to Present at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-29-17 07:55AM  Is Neurocrine Biosciences Incs (NASDAQ:NBIX) Balance Sheet A Threat To Its Future? Simply Wall St.
Dec-19-17 11:42AM  Why Biotech Acadia May Be Undervalued By 40% Investopedia
Dec-15-17 08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-13-17 08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-12-17 08:10AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-11-17 08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-07-17 01:15PM  Neurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference PR Newswire
08:02AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-05-17 08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Dec-04-17 04:01PM  Neurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms PR Newswire
Nov-29-17 04:01PM  Neurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the American College of Neuropsychopharmacology Annual Meeting PR Newswire
08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-28-17 08:06AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-21-17 01:15PM  Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference PR Newswire
08:15AM  Detailed Research: Economic Perspectives on Nexstar Broadcasting Group, CECO Environmental, Performance Food Group, Neurocrine Biosciences, e.l.f. Beauty, and Big Lots What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-20-17 04:01PM  Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer PR Newswire
08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-16-17 09:42AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-15-17 08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-14-17 01:34PM  Neurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical Psychiatry PR Newswire
08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-09-17 04:01PM  INGREZZA®, First FDA Approved Product for the Treatment of Tardive Dyskinesia, Receives Outstanding Therapeutic Product Award from Prestigious California Life Sciences Association PR Newswire
Nov-08-17 01:15PM  Neurocrine Biosciences to Present at the Jefferies 2017 London Healthcare Conference PR Newswire
Nov-07-17 10:12PM  Edited Transcript of NBIX earnings conference call or presentation 1-Nov-17 9:00pm GMT Thomson Reuters StreetEvents
04:01PM  Neurocrine to Present Data on the Patient Impact of Tardive Dyskinesia from the RE-KINECT Study at the 2017 Neuroscience Education Institute Congress PR Newswire
07:55AM  Neurocrine stock rockets to a record on sales beatbut can it last? MarketWatch
Nov-03-17 08:10AM  Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Alnylam Pharmaceuticals ACCESSWIRE
03:00AM  Stocks Showing Market Leadership: Neurocrine Biosciences Earns 96 RS Rating Investor's Business Daily
Nov-02-17 05:00PM  NBIX: INGREZZA® Revenues Way Ahead of Forecasts In 3Q17 Zacks Small Cap Research +19.45%
01:48PM  Neurocrine Biosciences Exceeds Expectations With Ingrezza Launch Benzinga
01:10PM  Here's Why Neurocrine Biosciences Is Soaring Motley Fool
09:35AM  Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers TheStreet.com
08:06AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Nov-01-17 05:47PM  Neurocrine, Exelixis, Juno Stocks Rocket After Crushing Views Investor's Business Daily
04:31PM  Neurocrine reports 3Q loss Associated Press
04:01PM  Neurocrine Biosciences Reports Third Quarter 2017 Results PR Newswire
01:10PM  Neurocrine Biosciences, Inc. to Host Earnings Call ACCESSWIRE
12:00PM  AbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain PR Newswire
Oct-31-17 01:15PM  Neurocrine Biosciences to Present at the Credit Suisse 26th Annual Healthcare Conference PR Newswire
Oct-30-17 08:06AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
07:30AM  Corporate News Blog - AbbVie Gets US FDA Priority Review for Elagolix for the Management of Endometriosis and Associated Pain ACCESSWIRE
Oct-27-17 08:04AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
07:00AM  AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain PR Newswire
Oct-25-17 04:01PM  Neurocrine Initiates Phase IIb Clinical Study of Once-daily INGREZZA® in Children and Adolescents with Tourette Syndrome PR Newswire
08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Oct-24-17 01:23PM  Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2017 Results PR Newswire
Oct-23-17 04:56PM  Neurocrine Granted FDA Orphan Drug Designation for Valbenazine for the Treatment of Pediatric Patients With Tourette Syndrome PR Newswire
08:04AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Oct-18-17 08:04AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Oct-16-17 01:23PM  How Is Neurocrine Biosciences Positioned Now? Market Realist
09:43AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Oct-13-17 08:04AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Oct-12-17 08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Oct-10-17 08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Oct-06-17 08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Oct-05-17 09:18AM  UPDATED: Neurocrine stock up 3% on higher-dose approval of tardive dyskinesia drug MarketWatch
08:05AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
07:00AM  Neurocrine Announces FDA Approval of 80 mg INGREZZA® (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD) PR Newswire
Sep-25-17 08:02AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Sep-22-17 08:02AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
08:00AM  Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Biocryst Pharmaceuticals ACCESSWIRE
03:00AM  Stocks To Watch: Neurocrine Biosciences Sees Relative Strength Rating Jump To 91 Investor's Business Daily
Sep-18-17 08:03AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Sep-15-17 09:25AM  Neurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the 2017 Annual Psych Congress PR Newswire
Sep-12-17 08:04AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Sep-11-17 08:04AM  See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. Markit
Sep-06-17 02:00PM  Neurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference PR Newswire
08:01AM  AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain PR Newswire
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL ? Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LYONS GARY ADirectorApr 03Option Exercise7.0515,000105,750277,066Apr 05 06:52 PM
Bozigian Haig P.Chief Development OfficerMar 05Option Exercise12.8775,873976,703197,471Mar 07 04:13 PM
Gano KyleChief Business Development OffMar 05Option Exercise8.6523,650204,573102,392Mar 07 04:16 PM
Lippoldt DarinChief Legal OfficerMar 05Option Exercise18.151,97935,91918,041Mar 07 04:18 PM
Lippoldt DarinChief Legal OfficerMar 05Sale88.471,979175,09016,062Mar 07 04:18 PM
Gano KyleChief Business Development OffMar 05Sale90.0023,6502,128,50078,742Mar 07 04:16 PM
Bozigian Haig P.Chief Development OfficerMar 05Sale90.0075,8736,828,570135,997Mar 07 04:13 PM
LYONS GARY ADirectorFeb 15Sale84.675,000423,341262,066Feb 20 04:02 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 12Option Exercise8.6614,593126,37597,535Feb 13 04:12 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 12Sale80.0014,5931,167,45382,942Feb 13 04:12 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 09Option Exercise8.6671,775621,572154,717Feb 13 04:12 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 09Sale77.9871,7755,596,72082,942Feb 13 04:12 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 06Option Exercise5.76100,000576,000442,874Feb 07 06:06 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 06Sale80.07100,0008,006,620342,874Feb 07 06:06 PM
Lippoldt DarinChief Legal OfficerFeb 05Option Exercise18.151,97935,91915,136Feb 07 06:07 PM
LYONS GARY ADirectorFeb 05Sale83.085,000415,380267,066Feb 07 06:08 PM
OBrien Christopher FlintFormer Chief Medical OfficerFeb 05Sale83.182,613217,34152,223Feb 07 06:08 PM
Lippoldt DarinChief Legal OfficerFeb 05Sale83.122,737227,49413,157Feb 07 06:07 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 05Sale83.1996079,86313,982Feb 07 06:07 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 05Sale83.092,046169,99780,691Feb 07 06:06 PM
Bozigian Haig P.Chief Development OfficerFeb 05Sale83.102,262187,977132,601Feb 07 06:05 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 05Sale83.265,983498,164339,482Feb 07 06:06 PM
BENEVICH ERICChief Commercial OfficerFeb 05Sale83.1482068,1742,577Feb 07 06:00 PM
Gano KyleChief Business Development OffFeb 05Sale83.052,046169,91476,950Feb 07 05:59 PM
RASTETTER WILLIAM HDirectorJan 24Option Exercise7.0520,000141,00034,250Jan 26 04:04 PM
RASTETTER WILLIAM HDirectorJan 24Sale90.009,500855,00024,750Jan 26 04:04 PM
OBrien Christopher FlintChief Medical OfficerJan 16Sale79.141,750138,49950,723Jan 18 04:12 PM
Grigoriadis Dimitri E.Chief Research OfficerJan 16Sale79.121,625128,56379,316Jan 18 04:10 PM
GORMAN KEVIN CHARLESChief Executive OfficerJan 16Sale78.893,750295,820336,357Jan 18 04:09 PM
Gano KyleChief Business Development OffJan 16Sale79.051,625128,46074,871Jan 18 04:08 PM
Bozigian Haig P.Chief Development OfficerJan 16Sale79.121,625128,575131,226Jan 18 04:07 PM
Lippoldt DarinChief Legal OfficerJan 03Option Exercise18.151,97935,91915,136Jan 04 04:07 PM
Lippoldt DarinChief Legal OfficerJan 03Sale79.361,979157,05313,157Jan 04 04:07 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 02Option Exercise15.4518,084279,39831,101Jan 04 04:05 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 02Sale77.5218,0841,401,82313,017Jan 04 04:05 PM
Lippoldt DarinChief Legal OfficerDec 28Option Exercise18.1515,237276,55228,394Jan 02 04:02 PM
Lippoldt DarinChief Legal OfficerDec 28Sale75.0015,2371,142,77513,157Jan 02 04:02 PM
Lippoldt DarinChief Legal OfficerDec 08Option Exercise18.152,95553,63316,112Dec 11 04:48 PM
Lippoldt DarinChief Legal OfficerDec 08Sale75.002,955221,62513,157Dec 11 04:48 PM
Lippoldt DarinChief Legal OfficerDec 04Option Exercise18.156,279113,96419,436Dec 06 04:59 PM
Lippoldt DarinChief Legal OfficerDec 04Sale75.046,279471,16013,157Dec 06 04:59 PM
LYONS GARY ADirectorDec 01Sale72.9210,000729,182272,066Dec 05 04:31 PM
Lippoldt DarinChief Legal OfficerNov 15Option Exercise18.159,900179,68523,057Nov 17 04:29 PM
Lippoldt DarinChief Legal OfficerNov 15Sale73.059,900723,19113,157Nov 17 04:29 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 08Sale74.5830,0002,237,34377,691Nov 13 04:15 PM
Gano KyleChief Business Development OffNov 02Option Exercise8.6624,818214,81086,714Nov 06 04:44 PM
OBrien Christopher FlintChief Medical OfficerNov 02Option Exercise8.6652,817457,32094,272Nov 06 04:45 PM
OBrien Christopher FlintChief Medical OfficerNov 02Sale69.7152,8173,681,64148,973Nov 06 04:45 PM
Gano KyleChief Business Development OffNov 02Sale71.0524,8181,763,31973,246Nov 06 04:44 PM
OBrien Christopher FlintChief Medical OfficerOct 02Option Exercise8.656,92559,90155,898Oct 03 07:14 PM
OBrien Christopher FlintChief Medical OfficerOct 02Sale61.046,925422,70248,973Oct 03 07:14 PM
Gano KyleChief Business Development OffSep 06Option Exercise8.6520,393176,39993,639Oct 03 07:13 PM
Bozigian Haig P.Chief Development OfficerSep 06Option Exercise13.3426,250350,138144,601Sep 08 02:58 PM
Lippoldt DarinChief Legal OfficerSep 06Option Exercise18.151001,81513,257Sep 08 02:59 PM
Gano KyleChief Business Development OffSep 06Option Exercise8.654,60739,85177,853Sep 08 02:58 PM
Gano KyleChief Business Development OffSep 06Sale60.004,607276,42073,246Sep 08 02:58 PM
Lippoldt DarinChief Legal OfficerSep 06Sale60.001006,00013,157Sep 08 02:59 PM
Bozigian Haig P.Chief Development OfficerSep 06Sale60.0026,2501,575,000129,601Sep 08 02:58 PM
Gano KyleChief Business Development OffSep 06Sale60.0020,3931,223,58073,246Oct 03 07:13 PM
OBrien Christopher FlintChief Medical OfficerSep 05Option Exercise8.6652,817457,395101,790Sep 07 05:55 PM
OBrien Christopher FlintChief Medical OfficerSep 05Sale57.5052,8173,036,97848,973Sep 07 05:55 PM
Lippoldt DarinChief Legal OfficerAug 09Option Exercise18.155,00090,75018,157Aug 14 12:30 PM
Grigoriadis Dimitri E.Chief Research OfficerAug 09Option Exercise5.7615,35488,439123,045Aug 14 12:29 PM
Lippoldt DarinChief Legal OfficerAug 09Sale55.005,000275,00013,157Aug 14 12:30 PM
Grigoriadis Dimitri E.Chief Research OfficerAug 09Sale55.0015,354844,470107,691Aug 14 12:29 PM
Bozigian Haig P.Chief Development OfficerAug 04Option Exercise7.0545,000317,200154,601Aug 08 05:44 PM
Bozigian Haig P.Chief Development OfficerAug 04Sale50.0022,5001,125,000129,601Aug 08 05:44 PM
OBrien Christopher FlintChief Medical OfficerJul 27Option Exercise8.658,73475,54957,707Jul 31 04:29 PM
OBrien Christopher FlintChief Medical OfficerJul 27Sale50.008,734436,70048,973Jul 31 04:29 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 23Sale53.3910,000533,900107,691May 24 04:13 PM
Lloyd-Smith MalcolmChief Regulatory OfficerMay 19Option Exercise15.454,98076,94117,997May 23 04:34 PM
Lloyd-Smith MalcolmChief Regulatory OfficerMay 19Sale54.004,980268,92013,017May 23 04:34 PM
Lippoldt DarinChief Legal OfficerMay 18Option Exercise18.1510,000181,50023,157May 23 04:34 PM
Lloyd-Smith MalcolmChief Regulatory OfficerMay 18Option Exercise15.454,98076,94117,997May 23 04:34 PM
OBrien Christopher FlintChief Medical OfficerMay 18Option Exercise6.36105,634671,915154,607May 23 04:36 PM
OBrien Christopher FlintChief Medical OfficerMay 18Sale53.32105,6345,632,40548,973May 23 04:36 PM
Lloyd-Smith MalcolmChief Regulatory OfficerMay 18Sale53.264,980265,23513,017May 23 04:34 PM
Lippoldt DarinChief Legal OfficerMay 18Sale53.2710,000532,70013,157May 23 04:34 PM
Nevinny Corinne HDirectorMay 05Sale53.985,000269,90034,603May 08 08:22 PM
Nevinny Corinne HDirectorMay 03Option Exercise3.4015,00051,00040,555May 05 01:26 PM
POPS RICHARD FDirectorMay 03Option Exercise3.4015,00051,00030,454May 05 01:27 PM
GORMAN KEVIN CHARLESChief Executive OfficerMay 02Option Exercise2.5921,73956,304354,346May 03 06:42 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 02Sale55.0010,000550,000117,691May 03 06:43 PM
GORMAN KEVIN CHARLESChief Executive OfficerMay 02Sale53.2321,7391,157,167332,607May 03 06:42 PM
Gano KyleChief Business Development OffMay 01Option Exercise2.5915,00038,85088,246May 03 06:41 PM
Gano KyleChief Business Development OffMay 01Sale54.0015,000810,00073,246May 03 06:41 PM